{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:27:04Z","timestamp":1787563624085,"version":"build-2736575974"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32DA007234"],"award-info":[{"award-number":["T32DA007234"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32DA007097"],"award-info":[{"award-number":["T32DA007097"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-15-1-0494"],"award-info":[{"award-number":["W81XWH-15-1-0494"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jpet.2026.104891","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:37:53Z","timestamp":1776728273000},"page":"104891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic and pharmacological characterization of novel agmatine-based antihyperalgesic compounds"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8032-0298","authenticated-orcid":false,"given":"Benjamin M.","family":"Clements","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7132-5310","authenticated-orcid":false,"given":"Cristina D.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parker","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8117-6565","authenticated-orcid":false,"given":"Kelley F.","family":"Kitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8700-0527","authenticated-orcid":false,"given":"Lukas D.","family":"Caye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7982-8086","authenticated-orcid":false,"given":"Cecilia","family":"Barajas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar R.","family":"Jakkaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyup","family":"Akg\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8900-9460","authenticated-orcid":false,"given":"Gunda I.","family":"Georg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6411-0423","authenticated-orcid":false,"given":"George L.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4252-8586","authenticated-orcid":false,"given":"Carolyn A.","family":"Fairbanks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10258","key":"10.1016\/j.jpet.2026.104891_bib1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"issue":"10289","key":"10.1016\/j.jpet.2026.104891_bib2","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: an update on burden, best practices, and new advances","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jpet.2026.104891_bib3","article-title":"A review of potential adverse effects of long-term opioid therapy: a practitioner's guide","volume":"14","author":"Baldini","year":"2012","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.jpet.2026.104891_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114147","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective","volume":"180","author":"Bindu","year":"2020","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"10.1016\/j.jpet.2026.104891_bib5","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1523\/JNEUROSCI.13-12-05228.1993","article-title":"Long-term potentiation and long-term depression of primary afferent neurotransmission in the rat spinal cord","volume":"13","author":"Randi\u0107","year":"1993","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.jpet.2026.104891_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0304-3959(91)90100-C","article-title":"The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states","volume":"44","author":"Woolf","year":"1991","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.jpet.2026.104891_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/17512433.2020.1717947","article-title":"Emerging concepts on the use of ketamine for chronic pain","volume":"13","author":"Yang","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.jpet.2026.104891_bib8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/AJP.0000000000000547","article-title":"A systematic review of NMDA receptor antagonists for treatment of neuropathic pain in clinical practice","volume":"34","author":"Aiyer","year":"2018","journal-title":"Clin J Pain"},{"issue":"14","key":"10.1016\/j.jpet.2026.104891_bib9","doi-asserted-by":"crossref","first-page":"e1652","DOI":"10.1212\/WNL.0000000000007238","article-title":"NMDA receptor antagonists and pain relief: a meta-analysis of experimental trials","volume":"92","author":"Thompson","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jpet.2026.104891_bib10","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s11030-023-10656-0","article-title":"GluN2B subunit selective N-methyl-D-aspartate receptor ligands: democratizing recent progress to assist the development of novel neurotherapeutics","volume":"28","author":"Ugale","year":"2024","journal-title":"Mol Divers"},{"issue":"2","key":"10.1016\/j.jpet.2026.104891_bib11","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1152\/jn.00172.2018","article-title":"Agmatine preferentially antagonizes GluN2B-containing N-methyl-d-aspartate receptors in spinal cord","volume":"121","author":"Waataja","year":"2019","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.jpet.2026.104891_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/17448069211029171","article-title":"Agmatine requires GluN2B-containing NMDA receptors to inhibit the development of neuropathic pain","volume":"17","author":"Peterson","year":"2021","journal-title":"Mol Pain"},{"issue":"5149","key":"10.1016\/j.jpet.2026.104891_bib13","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1126\/science.7906055","article-title":"Agmatine: an endogenous clonidine-displacing substance in the brain","volume":"263","author":"Li","year":"1994","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.jpet.2026.104891_bib14","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1097\/00001756-200009280-00031","article-title":"Agmatine improves locomotor function and reduces tissue damage following spinal cord injury","volume":"11","author":"Yu","year":"2000","journal-title":"Neuroreport"},{"issue":"3","key":"10.1016\/j.jpet.2026.104891_bib15","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1124\/jpet.107.123018","article-title":"Agmatine induces antihyperalgesic effects in diabetic rats and a superadditive interaction with R(-)-3-(2-carboxypiperazine-4-yl)-propyl-1-phosphonic acid, a N-methyl-D-aspartate-receptor antagonist","volume":"322","author":"Courteix","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.jpet.2026.104891_bib16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/fcp.12351","article-title":"Agmatine co-treatment attenuates allodynia and structural abnormalities in cisplatin-induced neuropathy in rats","volume":"32","author":"Donertas","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"issue":"19","key":"10.1016\/j.jpet.2026.104891_bib17","doi-asserted-by":"crossref","first-page":"10584","DOI":"10.1073\/pnas.97.19.10584","article-title":"Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury","volume":"97","author":"Fairbanks","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2-3","key":"10.1016\/j.jpet.2026.104891_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(99)00060-6","article-title":"Effect of intrathecal agmatine on inflammation-induced thermal hyperalgesia in rats","volume":"368","author":"Horv\u00e1th","year":"1999","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104891_bib19","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1526-4637.2010.00808.x","article-title":"Safety and efficacy of dietary agmatine sulfate in lumbar disc-associated radiculopathy. An open-label, dose-escalating study followed by a randomized, double-blind, placebo-controlled trial","volume":"11","author":"Keynan","year":"2010","journal-title":"Pain Med"},{"issue":"2","key":"10.1016\/j.jpet.2026.104891_bib20","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3390\/nu12020576","article-title":"Evidence for dietary agmatine sulfate effectiveness in neuropathies associated with painful small fiber neuropathy. A pilot open-label consecutive case series study","volume":"12","author":"Rosenberg","year":"2020","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.jpet.2026.104891_bib21","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0022-3565(25)23002-6","article-title":"Arcaine uncovers dual interactions of polyamines with the N-methyl-D-aspartate receptor","volume":"255","author":"Reynolds","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.jpet.2026.104891_bib22","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0022-3565(24)37988-1","article-title":"Agmatine selectively blocks the N-methyl-D-aspartate subclass of glutamate receptor channels in rat hippocampal neurons","volume":"288","author":"Yang","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.jpet.2026.104891_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1042\/bj3160247","article-title":"Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine","volume":"316","author":"Galea","year":"1996","journal-title":"Biochem J"},{"issue":"3","key":"10.1016\/j.jpet.2026.104891_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2024.100061","article-title":"Agmatine inhibits NMDA receptor\u2013mediated calcium transients in mouse spinal cord dorsal horn via intact PSD95-nNOS signaling","volume":"392","author":"Xie","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.jpet.2026.104891_bib25","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0028-3908(98)00218-4","article-title":"Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn","volume":"38","author":"Boyce","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpet.2026.104891_bib26","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1038\/srep04094","article-title":"GluN2B and GluN2D NMDARs dominate synaptic responses in the adult spinal cord","volume":"4","author":"Hildebrand","year":"2014","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.jpet.2026.104891_bib27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.123.001828","article-title":"Biodistribution of agmatine to brain and spinal cord after systemic delivery","volume":"387","author":"Clements","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2026.104891_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1196\/annals.1304.007","article-title":"Agmatine crosses the blood-brain barrier","volume":"1009","author":"Piletz","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.jpet.2026.104891_bib29","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1124\/jpet.105.086173","article-title":"Pharmacodynamic and pharmacokinetic studies of agmatine after spinal administration in the mouse","volume":"314","author":"Roberts","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2026.104891_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1196\/annals.1304.005","article-title":"Gastrointestinal uptake of agmatine: distribution in tissues and organs and pathophysiologic relevance","volume":"1009","author":"Molderings","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.jpet.2026.104891_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49078-0","article-title":"Safety and neurochemical profiles of acute and sub-chronic oral treatment with agmatine sulfate","volume":"9","author":"Bergin","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jpet.2026.104891_bib32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1476-5381.2009.00300.x","article-title":"Disruption of nNOS-PSD95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents","volume":"158","author":"Florio","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"7","key":"10.1016\/j.jpet.2026.104891_bib33","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.pain.2014.03.012","article-title":"The VGF-derived peptide TLQP-21 contributes to inflammatory and nerve injury-induced hypersensitivity","volume":"155","author":"Fairbanks","year":"2014","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.jpet.2026.104891_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-3565(25)39258-X","article-title":"Nociceptive action of excitatory amino acids in the mouse: effects of spinally administered opioids, phencyclidine and sigma agonists","volume":"243","author":"Aanonsen","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2026.104891_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0304-3940(92)90790-E","article-title":"Involvement of nitric oxide in spinally mediated hyperalgesia in the mouse","volume":"148","author":"Kitto","year":"1992","journal-title":"Neurosci Lett"},{"issue":"8","key":"10.1016\/j.jpet.2026.104891_bib36","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0169-409X(03)00101-7","article-title":"Spinal delivery of analgesics in experimental models of pain and analgesia","volume":"55","author":"Fairbanks","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"issue":"2\u20133","key":"10.1016\/j.jpet.2026.104891_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0014-2999(80)90515-4","article-title":"Intrathecal morphine in mice: a new technique","volume":"67","author":"Hylden","year":"1980","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104891_bib38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0304-3959(89)90135-8","article-title":"Expansion of receptive fields of spinal lamina I projection neurons in rats with unilateral adjuvant-induced inflammation: the contribution of dorsal horn mechanisms","volume":"37","author":"Hylden","year":"1989","journal-title":"Pain"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2026.104891_bib39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0304-3959(02)00333-0","article-title":"Up-regulation and trafficking of delta opioid receptor in a model of chronic inflammation: implications for pain control","volume":"101","author":"Cahill","year":"2003","journal-title":"Pain"},{"issue":"11","key":"10.1016\/j.jpet.2026.104891_bib40","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jpain.2013.06.008","article-title":"An overview of animal models of pain: disease models and outcome measures","volume":"14","author":"Gregory","year":"2013","journal-title":"J Pain"},{"issue":"1","key":"10.1016\/j.jpet.2026.104891_bib41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1476-5381.1963.tb01508.x","article-title":"Chemotherapy of arthritis induced in rats by mycobacterial adjuvant","volume":"21","author":"Newbould","year":"1963","journal-title":"Br J Pharmacol Chemother"},{"key":"10.1016\/j.jpet.2026.104891_bib42","series-title":"Manual of Pharmacologic Calculations with Computer Programs","author":"Tallarida","year":"1981"},{"issue":"3","key":"10.1016\/j.jpet.2026.104891_bib43","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/0040-4020(89)80106-1","article-title":"A convenient approach to the synthesis of prenyl-, furo- and pyrano-quinoline alkaloids of the rutaceae","volume":"45","author":"Shobana","year":"1989","journal-title":"Tetrahedron"},{"issue":"1","key":"10.1016\/j.jpet.2026.104891_bib44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1039\/C0OB00636J","article-title":"Total syntheses of subereamollines A and B","volume":"9","author":"Shearman","year":"2011","journal-title":"Org Biomol Chem"},{"issue":"4","key":"10.1016\/j.jpet.2026.104891_bib45","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/anie.201508713","article-title":"Small cause, great impact: modification of the guanidine group in the RGD motif controls integrin subtype selectivity","volume":"55","author":"Kapp","year":"2016","journal-title":"Angew Chem Int Ed"},{"issue":"9","key":"10.1016\/j.jpet.2026.104891_bib46","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/cmdc.201100241","article-title":"Application of the guanidine-acylguanidine bioisosteric approach to argininamide-type NPY Y2 receptor antagonists","volume":"6","author":"Pluym","year":"2011","journal-title":"ChemMedChem"},{"issue":"9","key":"10.1016\/j.jpet.2026.104891_bib47","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1021\/jo00385a010","article-title":"Total synthesis of (.+-.)-15-deoxyspergualin","volume":"52","author":"Bergeron","year":"1987","journal-title":"J Org Chem"},{"key":"10.1016\/j.jpet.2026.104891_bib48","first-page":"2006","article-title":"inventors, Gyrase inhibitors and uses thereof","author":"Charifson","year":"2006","journal-title":"U.S. patent US20060025424A1"},{"issue":"4","key":"10.1016\/j.jpet.2026.104891_bib49","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/jhet.5570270461","article-title":"Potential antitumor agents. IV. Pyrrole analogues of oncodazole","volume":"27","author":"Massa","year":"1990","journal-title":"J Heterocycl Chem"},{"issue":"2","key":"10.1016\/j.jpet.2026.104891_bib50","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1124\/jpet.109.155424","article-title":"Immunoneutralization of agmatine sensitizes mice to micro-opioid receptor tolerance","volume":"331","author":"Wade","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2026.104891_bib51","first-page":"562","article-title":"Bioavailability studies of calcium dobesilate--a case of flip-flop kinetics","volume":"40","author":"Franke","year":"1985","journal-title":"Pharmazie"},{"issue":"1","key":"10.1016\/j.jpet.2026.104891_bib52","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0168-3659(00)00374-6","article-title":"Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation","volume":"71","author":"Stepensky","year":"2001","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/j.jpet.2026.104891_bib53","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/bdd.513","article-title":"Evidence of a flip-flop phenomenon in acamprosate pharmacokinetics: an in vivo study in rats","volume":"27","author":"Zornoza","year":"2006","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"10.1016\/j.jpet.2026.104891_bib54","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7150\/thno.22711","article-title":"Recent advances in the application of vitamin E TPGS for drug delivery","volume":"8","author":"Yang","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.jpet.2026.104891_bib55","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuroscience.2012.09.013","article-title":"Ageing alters behavioural function and brain arginine metabolism in male Sprague-Dawley rats","volume":"226","author":"Gupta","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.jpet.2026.104891_bib56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neuroscience.2015.11.002","article-title":"Region-specific changes in presynaptic agmatine and glutamate levels in the aged rat brain","volume":"312","author":"Jing","year":"2016","journal-title":"Neuroscience"},{"issue":"9","key":"10.1016\/j.jpet.2026.104891_bib57","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/hipo.20448","article-title":"Effects of aging on agmatine levels in memory-associated brain structures","volume":"18","author":"Liu","year":"2008","journal-title":"Hippocampus"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526010906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526010906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:31:39Z","timestamp":1783182699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526010906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0022356526010906"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104891","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic and pharmacological characterization of novel agmatine-based antihyperalgesic compounds","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104891","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"104891"}}